Eli Lilly and Company (NYSE:LLY - Get Free Report) was down 1.3% during trading on Tuesday. The company traded as low as $1,401.66 and last traded at $1,412.6350. 2,466,539 shares traded hands during trading, a decline of 17% from the average session volume of 2,956,533 shares. The stock had previously closed at $1,431.67.
Eli Lilly and Company News Roundup
Investors following LLY have been watching these news items:
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. Morgan Stanley upped their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an "overweight" rating in a research report on Friday, October 30th. Citigroup boosted their price objective on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a "buy" rating in a research note on Friday, October 30th. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an "overweight" rating in a report on Friday, October 30th. Jefferies Financial Group boosted their price target on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a "buy" rating in a research report on Monday, November 9th. Finally, Guggenheim raised their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a "buy" rating in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $1,422.00.
Get Our Latest Stock Analysis on LLY
Eli Lilly and Company Trading Down 1.3%
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm's 50 day moving average is $1,247.93 and its 200 day moving average is $1,112.33. The company has a market capitalization of $1.33 trillion, a PE ratio of 45.85, a P/E/G ratio of 1.71 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company's revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $7.02 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 35.70 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's dividend payout ratio is presently 22.46%.
Insiders Place Their Bets
In related news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company's stock.
Institutional Trading of Eli Lilly and Company
Institutional investors have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock worth $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp increased its holdings in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Eli Lilly and Company in the second quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after buying an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC lifted its position in shares of Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after buying an additional 400,538 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
Eli Lilly and Company Company Profile
(
Get Free Report)
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.